To investigate levels of S100A4 protein in plasma and S100A4 mRNA in tumours from patients with clear cell renal cell carcinoma (CCRCC), and correlate these with metastasis, survival and levels of vascular endothelial growth factor (VEGF). METHODS: Plasma S100A4 and VEGF protein concentrations were measured using enzyme-linked immunosorbent assays in 39 healthy subjects and 68 consecutive patients with untreated CCRCC. Levels of S100A4 and VEGF mRNA in tumour and matched control (healthy) tissue samples were measured using realtime quantitative reverse transcriptionpolymerase chain reaction. Findings were analysed with respect to clinicopathological characteristics. RESULTS: Plasma VEGF concentrations were higher in patients with CCRCC than in healthy subjects. S100A4 and VEGF mRNA levels were up-regulated in CCRCC tumour tissue compared with control tissue samples. Logistic regression analysis revealed that up-regulated tumour S100A4 and VEGF mRNA levels were independent risk factors for the presence of invasion and/or metastasis. CONCLUSIONS: S100A4 and VEGF are associated with tumour invasion and metastasis, and may be useful prognostic markers in patients with CCRCC. S100A4 and VEGF may represent potential targets for therapeutic intervention.
Introduction
Over 90% of kidney cancers are believed to be of epithelial cell origin and are referred to as renal cell carcinomas (RCC); these carcinomas are subdivided based on histology into clear cell RCC (CCRCC; 75%), papillary RCC (15%), chromophobe tumours (5%) and oncocytomas (5%). 1 Radical nephrectomy is the usual surgical approach for RCC, but treatment is inadequate for cases that remain uncured following surgery. The main prognostic indicators for patients with RCC are local and metastatic extension of the tumour, with the presence or absence of metastasis at the time of diagnosis being the key factor for determining survival. 2 The expression of The calcium-binding protein S100A4 promotes metastasis in several experimental animal models and is associated with patient outcome in a number of tumour types. 5, 6 S100A4 is localized to the nucleus, cytoplasm and extracellular space, and possesses a wide range of biological functions including the regulation of angiogenesis, cell survival, motility and invasion. 5 -7 There is evidence to suggest that S100A4 may be a marker for the early detection of some cancers. 7 -9 Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis, 10 which is of crucial importance for tumour growth. Overexpression of VEGF in blood or tissue may be a useful marker for predicting survival and metastasis in many cancers. 11 -15 VEGF plays a role in the pathogenesis of RCC, since activation of the VEGF pathway is responsible for the recruitment, migration and expansion of endothelial cells. 16 The first drug to validate VEGF as a target in the treatment of CCRCC was the anti-VEGF monoclonal antibody, bevacizumab. 17 Sunitinib, a VEGF receptor inhibitor, is now a standard first-line therapy for advanced RCC and the VEGF receptor inhibitor sorafenib is among the second-line treatment options. 18 Overexpression of S100A4 and VEGF has been shown to play important roles in the development of pancreatic cancer, and the combined examination of these molecules might be useful in evaluating outcome in pancreatic cancer cases. 19 The current study measured plasma concentrations of S100A4 and VEGF protein, and levels of S100A4 and VEGF mRNA in CCRCC tissue, to investigate the correlation between S100A4 and VEGF levels, and metastasis and survival, in patients with CCRCC. Consequently, all patients were evaluated by routine examinations including chest X-ray, ultrasonography, computed tomography, magnetic resonance imaging and bone scintigraphy. Staging was performed according to the tumour-node-metastasis (TNM) classification system, 20 with T and N always defined as primary (p)T and pN. Patients with lymph node invasion were staged as N+. Metastasis was defined according to clinical findings if no histopathological data on metastases were available. Patients diagnosed with metastatic disease during the first month following surgery were staged as M+ for the purpose of this analysis. Nuclear grading was based on the criteria of Fuhrman et al. 21 and patients were divided into three groups for statistical evaluation (G1, G2, and G3 -G4). The diameter of the primary tumour was H Yang, K Zhao, Q Yu et al. S100A4: metastatic and prognostic marker in CCRCC measured and classified as > 7 cm or ≤ 7 cm.
Patients and methods

STUDY POPULATION
Blood donors attending the Second Hospital of Tianjin Medical University, Tianjin, China were recruited as healthy control subjects in order to establish the normal plasma levels of S100A4 and VEGF. Control subjects were confirmed as being healthy by clinical examination and routine laboratory tests, including screening for anti-HIV, antihepatitis B core antigen, antihepatitis C virus antibodies, hepatitis B surface antigen, serum aminotransferase and serological tests for syphilis. Control subjects were not matched for age or gender.
The Ethics Committee of the Second Hospital of Tianjin Medical University approved the study protocol and all study participants provided written informed consent.
BLOOD SAMPLE COLLECTION
Venous blood was obtained from control subjects during blood donation and from patients on the day before surgery. Blood was collected into ethylenediaminetetra-acetic acid (EDTA)-coated sterile tubes (final concentration, 1.28% EDTA). Plasma was separated by centrifugation at 3000 g for 3 min and immediately frozen at -80°C in aliquots of 0.5 ml, until analysis.
PLASMA VEGF AND S100A4 MEASUREMENT
Plasma levels of VEGF and S100A4 were measured using enzyme-linked immunosorbent assay kits (VEGF [165 amino acid form], BD Pharmingen, San Jose, CA, USA; S100A4, Calbiochem, Darmstadt, Germany), according to the manufacturers' protocols.
REAL-TIME QUANTITATIVE RT-PCR FOR VEGF AND S100A4 MRNA
Total RNA was extracted from cryostat sections of frozen tumour and matched control tissue (0.5 -1 g) from CCRCC patients, using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA). RNA extracted from tissue sections was reverse-transcribed in a final volume of 20 µl, using a Superscript ® II reverse transcriptase (RT) kit (Invitrogen), according to the manufacturer's instructions. The reactions were performed at 42°C for 50 min, followed by inactivation of the enzyme at 70°C for 15 min, and the resulting complementary DNA (cDNA) was stored at -20°C. Real-time quantitative polymerase chain reaction (PCR) analyses were performed using the ABI Prism 7700 Sequence Detection System instrumentation and software (Applied Biosystems, Foster City, CA, USA). Intron spanning primers and probes for the TaqMan ® system (Applied Biosystems) were designed using Primer Express software (Applied Biosystems) and were supplied by GenePharma, Shanghai, China. PCR primers for the S100A4 cDNA fragment were 5′-TCTTTCTTGGTTTGATCC TG-3′ (sense) and 5′-GCATCAAGCACGTGTC TGAA-3′ (antisense). Real-time quantitative PCR analysis was performed using a commercially available kit (Promega, Madison, WI, USA), as previously described. 22 The cycling programme involved preliminary denaturation at 94°C for 15 min, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 48°C for 5 s and elongation at 72°C for 15 s, followed by a final elongation step at 72°C for 2 min.
The VEGF 165 probe 5′-carboxyfluorescein-TGAATGCAGACCAAAGAAAGATAGAGCAA G-tetramethylrhodamine-3′, forward primer 5′-AGCTTCCTACAGCACAACAAATG-3′ and reverse primer 5′-CAAGGCCCACAGGGAT TTT-3′ were designed as previously described. 23 Real-time quantitative PCR analysis was performed using the commercially available kit (Promega). The H Yang, K Zhao, Q Yu et al. S100A4: metastatic and prognostic marker in CCRCC cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 20 s and elongation at 72°C for 15 s, followed by a final elongation step at 72°C for 3 min.
The housekeeping gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, using the primers 5′-ACAGTCAGCCGCA TCTTCTT-3′ (sense) and 5′TTGATTTTGGA GGGATCTCG-3′
(anti sense), and a commercially available kit (Beijing Tianwei Corporation, Beijing, China). 24 The cycling programme involved preliminary denaturation at 94°C for 15 min, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 58°C for 30 s and elongation at 72°C for 30 s, followed by a final elongation step at 60°C for 2 min.
Levels of VEGF and S100A4 mRNA were normalized to the housekeeping gene, GAPDH, to adjust for variances in the quality of the RNA and the amount of cDNA input. Changes in ratio ≥ 2 (compared with levels in control tissue samples) were termed upregulation and changes in ratio < 2 (compared with levels in control tissue samples) were termed down-regulation, as described previously. 23 
STATISTICAL ANALYSES
The plasma S100A4 and VEGF protein concentrations in different groups were presented as the median (range). Data were the mean of two measurements of each parameter. Between-group differences in plasma S100A4 and VEGF concentrations, and S100A4 and VEGF mRNA levels in CCRCC tissue, were analysed using the Wilcoxon signed-rank test. The KruskalWallis test was used to evaluate the relationship between plasma and tissue S100A4 and VEGF levels, and the different clinical parameters and staging characteristics of patients with CCRCC. Correlation coefficients between the different parameters were calculated using the nonparametric Spearman's rank correlation coefficient test. The follow-up period for survival analysis ended on 31 December 2010. Overall survival rates were measured from the date of treatment (i.e. the date of surgery) to the study endpoints, which were the end of the follow-up period, the date of death from any cause or the time of the last visit before the patient was lost to follow-up. Significant variables identified on univariate analysis were subjected to multivariate analysis using the Cox regression model. Relationships between overall survival and plasma VEGF or S100A4 concentrations were determined using Kaplan-Meier survival analyses. Features that were independently associated with overall survival were identified in multivariate analysis with Cox proportional hazard regression analysis. Differences between the survival curves were tested using the log-rank test. Statistical analyses were performed using SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered statistically significant.
Results
The study included 68 patients with untreated CCRCC (58 males, 10 females; mean ± SD age 58.8 ± 10.4 years; age range 24 -81 years) and 39 healthy control subjects (31 males, eight females; mean ± SD age 36.3 ± 5.4 years; age range 25 -56 years). All CCRCC patients underwent surgery including nephrectomy (radical, n = 60; partial, n = 5; enucleation, n = 3) and dissection of the lymph nodes of the latero-aortocaval area. Metastatic disease was diagnosed in two patients during the first month following surgery, and was H Yang, K Zhao, Q Yu et al. S100A4: metastatic and prognostic marker in CCRCC staged as M+ for the purposes of this analysis.
Plasma VEGF concentrations were significantly higher in patients with CCRCC than in control subjects (P = 0.006; Table 1 ). There were no significant differences in plasma VEGF concentrations in patients with or without metastases (M+ versus M-), but VEGF concentrations were significantly higher in patients with lymph node invasion (N+) and/or metastases (M+) than in patients with undisseminated CCRCC (M-N-; P = 0.025). Plasma VEGF concentrations were significantly higher in patients without metastases (n = 60) than in control subjects (P = 0.017), but did not correlate with the size of the primary tumour (data not shown).
There were no significant differences in plasma S100A4 concentrations between patients and controls, between patients with or without metastases, or between patients with lymph node invasion (N+) and/or metastases (M+) and patients with undisseminated CCRCC (M-N-) . There was a significant positive correlation between plasma S100A4 and VEGF concentrations in the patient group (r = 0.23; n = 68; P = 0.042), but there was no corresponding correlation in the control group (data not shown).
The median duration of follow-up was 54.6 months (range 36.2 -72.9 months). KaplanMeier survival analyses found no relationship between overall survival and plasma VEGF or S100A4 concentrations (data not shown). Multivariate analysis found that pretreatment plasma VEGF and S100A4 concentrations were not independent prognostic factors for survival (data not shown).
The results of the real-time RT-PCR analyses are shown in Table 2 . S100A4 mRNA was up-regulated in tumour tissue samples from 41/68 (60.3%) CCRCC patients, and VEGF mRNA was up-regulated in tumour tissue samples from 46/68 (67.6%) CCRCC patients. There was a significant association between S100A4 mRNA levels and VEGF mRNA levels (P < 0.01), but there was no corresponding correlation in control tissue samples (data not shown). As shown in Table 2 , S100A4 and VEGF mRNA levels Comparison between T1 and T2 -T4, N0 and N1 -N2, M0 and M1, or G1 and G2 or G3 -G4 (Kruskal-Wallis test). NS, No statistically significant differences (P ≥ 0.05).
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were significantly associated with TNM stage (P < 0.05 for all comparisons). No significant relationships were observed between nuclear grade and S100A4 mRNA or VEGF mRNA levels.
Logistic regression analyses were undertaken for tumour size (> 7 cm in diameter; Table 3 , model A) and the presence of invasion or metastasis (Table 3 , model B). High nuclear grade (G2 or G3 -G4), upregulated S100A4 mRNA and up-regulated VEGF mRNA were significant predictors of large tumour size and the presence of invasion or metastasis in univariate regression analysis. Multivariate analysis found that nuclear grade 3 -4 and upregulated tumour S100A4 and VEGF mRNA levels were independent risk factors for large tumour size and the presence of invasion or metastasis ( Table 3) .
The 5-year survival rates in patients with down-regulated or up-regulated tumour S100A4 expression were 90.5% and 68.4%, respectively (P < 0.05; Table 4 ). TNM staging and nuclear grade were significantly correlated with survival in patients with CCRCC (Table 4) . Cox proportional hazard analysis demonstrated that tumour and node classification stage, and an upregulated tumour S100A4 mRNA level, were independent factors for cause-specific survival (data not shown). In contrast, an up-regulated tumour VEGF mRNA level was not an independent factor for cause-specific survival (data not shown).
Discussion
The calcium-binding protein S100A4 -also known as mts1, p9Ka, FSP1, CAPL, calvasculin, pEL98, metastasin, 18A2 and 42A -was cloned from various cell systems. 5, 25 It is one of at least 21 members of the S100 protein family of calcium-binding, low molecular mass proteins (10 -12 kDa) that generally exist as homo-or heterodimers within cells. 26 and these functional states appear to be associated with extracellular activity. S100 proteins possess no enzymatic activity and exert their effects by interacting with (and modulating) the activities of other proteins. 5, 27 Altered expression levels of S100 proteins have been described in several human diseases such as cancer, inflammatory disorders, cardiomyopathies and neurodegenerative conditions. 28 The S100A4 protein is a small Ca 2+ -binding protein that is widely expressed in tumour cells and may predict metastasis and, therefore, outcome. 5, 6 In line with this reasoning, numerous studies have investigated the potential use of S100A4 as a prognostic marker. For example, in a study of 349 patients with breast cancer, Rudland et al. 29 identified the presence of S100A4 protein as the most significant predictor of patient survival, even when compared with wellestablished markers of disease progression. Of patients with S100A4-negative tumours, 80% were alive after 19 years' follow-up, compared with only 11% of those with S100A4-positive tumours. 29 These results have been confirmed in two separate patient cohorts, although the survival advantages in the S100A4-negative groups in these reports were less pronounced. 30, 31 Conflicting results have also been published, 32 but these discrepancies may be explained by fewer patients, a shorter observation period and differences in stage distribution and fixation methods. S100A4 is also overexpressed in colorectal cancer, 25, 33 and S100A4 mRNA and protein levels are both correlated with patient outcome. 7, 33 An association between S100A4 and patient survival has been shown in several other tumour types including ovarian carcinoma, pancreatic, malignant melanoma, bladder, nonsmall cell lung carcinoma, gallbladder, oesophageal squamous cell carcinoma and gastric cancer. 7 Prior to the present study, the prognostic significance of S100A4 has only been analysed in retrospective studies.
The present study found that plasma concentrations of S100A4 were elevated in a group of patients with CCRCC compared with healthy control subjects, but this H Yang, K Zhao, Q Yu et al. S100A4: metastatic and prognostic marker in CCRCC difference was not statistically significant. In addition, there were no significant differences in plasma S100A4 concentrations between patients with CCRCC with or without metastases, and this parameter did not appear to be a prognostic factor for metastasis. Since red blood cells and mononuclear cells contain and release S100A4, 34 they may contribute to the levels of S100A4 found in serum and plasma. Even very low-level haemolysis might influence the results, and the potential contribution from a S100A4-expressing tumour cannot be determined, suggesting that S100A4 is not suitable as a plasma or serum marker for CCRCC. In samples of CCRCC tumour tissue, however, S100A4 mRNA was significantly increased compared with matched control samples, and in metastatic tissue (M1) compared with nonmetastatic (M0) tissue. Patients with CCRCC in whom S100A4 mRNA tissue levels were up-regulated at diagnosis had a lower 5-year survival rate than patients in whom S100A4 mRNA tissue levels were down-regulated. In addition, this marker was an independent prognostic indicator.
The calcium-binding protein S100A4 is a well-established marker and mediator of metastatic disease, but the exact mechanisms responsible for these effects are poorly defined. Based on observations in transgenic mice, S100A4 has been identified as a potent stimulator of angiogenesis. 35 Ageing S100A4 transgenic mice were significantly more likely to develop liver haemangiomas compared with nontransgenic mice, and micropellets containing S100A4 induced neovascularization when implanted in the corneas of mice. 35 S100A4 was also associated with angiogenesis in neoplastic lesions, as shown in mammary tumours from S100A4 transgenic mice, which displayed higher vessel density compared with tumours from nontransgenic mice. 35 Vessel density and S100A4 expression were positively correlated in primary tumours from patients with breast cancer. 31 The mechanisms involved in this process are yet to be fully elucidated. Vascular endothelial growth factor is the most potent promoter of tumour-associated angiogenesis and has been exploited as a target for therapeutic inhibition. 36 Overexpression of S100A4 and VEGF plays an important role in the development of pancreatic cancer, and combined examination of the two molecules might be useful in evaluating the outcome of patients with such cancers. 19 Plasma concentrations of VEGF were significantly increased in patients with CCRCC compared with control subjects in the current study, and VEGF mRNA levels were up-regulated in tumour tissue samples compared with matched control tissue samples. There were also significant increases in tumour VEGF mRNA and plasma VEGF protein levels in patients with metastatic disease, compared with patients with no metastatic disease. Furthermore, in patients with CCRCC, a positive correlation was observed between S100A4 and VEGF levels in plasma, and S100A4 and VEGF mRNA levels in tumour tissue samples. These data suggest that S100A4 might induce tumour progression via stimulation of angiogenesis.
In summary, S100A4 and VEGF mRNA levels were up-regulated in CCRCC tumour tissue samples compared with matched control tissue samples, and were significantly correlated with some of the clinicopathological characteristics of CCRCC. S100A4 mRNA expression status was an independent prognostic predictor of survival in patients with CCRCC. The detection of S100A4 and VEGF mRNA in tumour tissues might help to evaluate the prognosis of
